Several resistance mechanisms have been identified in the treatment of HR-positive and HER2-negative advanced breast cancers, among which is the overactivation of the phosphatidylinositol 3-kinase (PI3K)-AKT-PTEN pathway. The gene discussed is ERBB2; the disease is breast cancer.